| 2026-08-21 | 8-K | Form 8-K, Item 8.01 |
| 2026-08-05 | Deck | Download our MNKD Investor Fact Sheet |
| 2026-08-05 | Press release | MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update |
| 2026-08-05 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-05 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-29 | Deck | INFLO‑1 Data Readout Presentation |
| 2026-07-29 | Press release | MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical |
| 2026-07-28 | Press release | MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026 |
| 2026-07-24 | Deck | U.S. FDA Approval of Furoscix ReadyFlow Autoinjector Presentation |
| 2026-07-24 | Press release | MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diureti |
| 2026-07-24 | Press release | MannKind Announces $50 Million Private Placement |
| 2026-07-24 | 8-K | Form 8-K, Item 3.02 |
| 2026-06-23 | Press release | MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with N |
| 2026-06-05 | Press release | Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) A |
| 2026-06-03 | Press release | MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment o |
| 2026-06-02 | 8-K | Form 8-K, Item 8.01 |
| 2026-06-01 | Deck | U.S. FDA Approval of Afrezza in Pediatrics Presentation |
| 2026-05-29 | Press release | MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval |
| 2026-05-29 | Press release | MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolesc |
| 2026-05-28 | 8-K | Form 8-K, Item 8.01 |
| 2026-05-27 | Press release | MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregn |
| 2026-05-27 | Press release | MannKind to Present at Jefferies Global Healthcare Conference |
| 2026-05-22 | 8-K | Form 8-K, Item 5.07 |
| 2026-05-06 | Deck | Q1 2026 Financial Results & Business Update |
| 2026-05-06 | Press release | MannKind Reports First Quarter 2026 Financial Results and Provides Business Update |
| 2026-05-06 | Press release | MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic L |
| 2026-05-06 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-06 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-29 | Press release | MannKind to Report First Quarter 2026 Financial Results on May 6, 2026 |
| 2026-04-07 | Proxy | Definitive proxy statement |
| 2026-03-09 | Press release | MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026 |
| 2026-03-05 | Press release | MannKind Announces Settlement of Convertible Senior Notes |
| 2026-03-04 | Press release | MannKind to Participate in Upcoming Investor Conferences |
| 2026-02-26 | Press release | MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update |
| 2026-02-26 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-26 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-19 | Press release | MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference |
| 2026-02-18 | Press release | MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 |
| 2026-02-09 | Press release | MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnos |
| 2026-01-26 | Press release | MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple |